DM4-SME is primarily utilized in the development of antibody-drug conjugates (ADCs) for targeted cancer therapy. It functions as a potent cytotoxic agent that is linked to monoclonal antibodies, which specifically recognize and bind to antigens on cancer cells. This targeted approach allows for the delivery of the cytotoxic payload directly to tumor cells, minimizing damage to healthy tissues and reducing systemic side effects. DM4-SME is particularly effective in treating various types of cancers, including breast cancer, lung cancer, and lymphomas, by inducing cell death through the inhibition of microtubule assembly, which disrupts cell division and leads to apoptosis. Its application in ADCs represents a significant advancement in precision medicine, offering improved therapeutic outcomes for patients with difficult-to-treat malignancies.